GSK agreed to acquire Rapt Therapeutics for $2.2 billion, taking control of ozureprubart, a mid‑phase anti‑IgE monoclonal antibody designed to prevent food‑allergy reactions. The deal gives GSK global rights outside China and accelerates its push into immunology and allergy, with the company planning Phase III studies following a Phase IIb program (prestIgE) currently underway. Rapt shareholders are to receive $58 per share; closing is expected in Q1 2026. Ozureprubart targets the validated IgE pathway and is being developed for extended dosing intervals (every 8–12 weeks) compared with current anti‑IgE therapy Xolair, which is dosed every 2–4 weeks. GSK framed the purchase as a way to reach a broader patient population, including those ineligible for existing anti‑IgE treatment due to high IgE or BMI. GSK’s chief scientific officer Tony Wood and Rapt’s leadership were cited in company statements about strategic fit and timeline expectations. Investors reacted positively, sending Rapt shares sharply higher on the announcement. The acquisition follows a recent wave of M&A activity as big pharmas seek late‑stage immunology assets; GSK will fund pivotal programs and prepare regulatory filings contingent on Phase IIb data due in 2027.